CRISPR/Cas9 Tool for MicroRNAs Editing in Cardiac Development, Function, and Disease

CRISPR/Cas9 Tool for MicroRNAs Editing in Cardiac Development, Function, and Disease
Leila Abkhooie,^1,*
1. Department of Medical Biotechnology, Faculty of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran
Introduction: There is emerging scientific proof that the CRISPR/Cas9 system can target small noncoding RNAs, like miRNAs. CRISPR/Cas9 technology provides a unique gene-editing approach with stability. MiRNA dysregulation can result in numerous diseases, such as a number of pathological processes associated with heart disease. Many miRNA molecules have been discovered as being involved in the modulation of fibrosis and cardiac hypertrophy, as well as the regulation of cardiomyocytes.
Methods: Pubmed, google sccholar
Results: The results demonstrate the high efficiency of the CRISPR/Cas9 method for studying the result of the deletion of miRNAs in cell physiology. Studies display that miRNAs strongly affect organ evolution and concentration of miRNAs can involve in the differentiation, development, and function of organs so that at low concentrations miRNAs may target one or a small group of mRNAs and at high concentrations, it may affect different groups of mRNAs. CRISPR/Cas9 tools can be used to eliminate small areas of DNA and determine miRNA in cases where similar groups of miRNAs are in the same strand, also CRISPR/Cas9 genome-editing method is more strong system in stopping miRNAs than previous methods such as antisense inhibitors.
Conclusion: we critically examine the current status and recent progress of miRNA-targeted therapeutics through the CRISPR/Cas9 system, besides another emerging strategies to specifically combine different delivery platforms and cell-fate engineering for the clarification of miRNA function and miRNA-based therapeutic intervention.
Keywords: CRISPR/Cas9, MicroRNAs, Cardiac Development and Disease